Nucleos(t)ide analogs continuation is not associated with a lower risk of HBsAg seroreversion following PEG-IFN-induced HBsAg loss

Table 2 Multivariable logistic analysis for predictors of HBsAg seroreversion

	Univariable analysis			Multivariable logistic analysis
	HBsAg seroreversion group (n = 43)	Non-HBsAg seroreversion group (n = 177)	P-value	OR	95% CI	P-value
Age (years)	40.49 ± 7.37	41.34 ± 8.65	0.514	0.985	0.938–1.034	0.540
Sex, male (n, %)	36 (83.7%)	144 (81.4%)	0.888	0.648	0.231–1.812	0.408
Serum ALT level (IU/mL)	52.00 (35.00, 70.500)	36.00 (25.00, 56.00)	0.001	1.007	0.998–1.015	0.127
Serum HBsAb level (Log mIU/mL)^a	1.39 (0.68, 1.69)	2.05 (1.25, 2.51)	< 0.001	0.388	0.245–0.616	< 0.001
NUCs consolidation (n%)	12 (27.9%)	42 (23.7%)	0.709	1.210	0.513–2.855	0.664
Serum HBsAg level before treatment (Log IU/mL)	2.36 (1.82, 2.70)	2.14 (1.39, 2.62)	0.126	1.442	0.785–2.650	0.238
PEG-IFN therapy duration required to achieve HBsAg loss (weeks)	36.00 (28.00, 42.00)	26.00(22.00, 46.00)	0.017	1.012	0.990–1.034	0.294
PEG-IFN consolidation treatment duration (weeks)	12.00 (5.00, 19.00)	12.00 (10.00, 24.00)	0.097	0.999	0.963–1.036	0.946
Compensated cirrhosis (n, %)^b	2 (4.7%)	10 (5.7%)	1.000	0.820	0.151–4.456	0.819

^a HBsAb detection was missing for one patient in the non-HBsAg seroreversion group
^b B ultrasound finding was missing for one patient in the non-HBsAg seroreversion group
HBsAb, hepatitis B surface antibody; HBsAg, Hepatitis B surface antigen; NUCs, nucleos(t)ide analogs; PEG-IFN, pegylated-interferon; HBV, hepatitis B virus; OR, odds ratio; CI, confidence interval; ALT, alanine aminotransferase

ISSN: 1743-422X